Belite Bio, Inc
BLTE
Pozycja w akcjach
#2971
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Cena akcji
$153.69
Kapitalizacja rynkowa
$6.19B
Zmiana (1 dzień)
-0.49%
Zmiana (1 rok)
67.05%
Kraj
US
Handel Belite Bio, Inc (BLTE)
Kategoria
Healthcare
Historia ceny akcji dla Belite Bio, Inc (BLTE)
Najwyższa cena zamknięcia: $154.24 dnia 2026-10-01
Najniższa cena zamknięcia: $10.59 dnia 2022-04-01
Najniższa cena zamknięcia: $10.59 dnia 2022-04-01
Historia cen akcji firmy Belite Bio, Inc od 2022 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 1.17% |
| 2025 | 137.93% |
| 2024 | 45.90% |
| 2023 | 43.40% |
| 2022 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $524.15 | 22.96% |
US
|
|
| $252.43 | 818.27% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $888.46 | 6.43% |
NL
|
|
| $752.87 | 7.40% |
CH
|
